RxDoctor Payments Data

Sam Hooshmand

Neurology · Milwaukee, WINPI 1417310665

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $139,254 of the $229,256 with a category attached, or 60.7%. 12 manufacturers reported payments, led by TG Therapeutics, Inc. at 39.0% of the total. 2025 is the largest year on record at $131,552, more than ten times the $2,380 reported in 2020. Among neurology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$229,256in general payments, 2019–2025

Across 236 payments — averaging $971.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • TG Therapeutics, Inc.$89K
  • EMD Serono, Inc.$86K
  • Genentech USA, Inc.$31K
  • Sanofi$13K
  • Amgen$8K
  • Novartis$1K
  • plus $812 from 6 others
$553,799in research payments, 2019–2025

Across 14 payments — averaging $39,557 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$538K
  • EMD Serono, Inc.$16K

What the payments were for

  • Consulting fees$54,79724%
  • Speaking & faculty fees$139,25461%
  • Travel & lodging$25,37111%
  • Food & beverage$9,8254%
  • Education$100%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$229,256 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Wisconsin.

See all neurology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$20,197
Medicare patients
98
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab30$266,671
NuedextaDextromethorphan Hbr/Quinidine16$27,014
Dalfampridine ErDalfampridine82$7,954
Gabapentin146$5,505
Baclofen182$4,371
Modafinil49$4,218
Carbamazepine50$2,535
AmantadineAmantadine Hcl25$2,495
Teriflunomide45$2,194
Sumatriptan Succinate19$1,655
Levetiracetam18$1,093
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine24$891
Topiramate25$826
Tizanidine Hcl57$818
Mirtazapine25$489

Paid to pharmacies, not to this prescriber.

Other neurology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →